ClinicalTrials.Veeva

Menu

Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence (IDEA)

5

59th Medical Wing

Status

Completed

Conditions

Motivation
Pre-diabetes
Diabetes Risk Score

Treatments

Other: diabetic risk score

Study type

Interventional

Funder types

Other U.S. Federal agency

Identifiers

NCT01932866
IDEA Trial

Details and patient eligibility

About

The purpose of this randomized, controlled study is to evaluate whether the knowledge of a personalized diabetes risk score affects adherence to a 12-week diet and exercise lifestyle change program in prediabetic patients. The intervention group will receive diabetes risk score results at the beginning of the twelve weeks, and the control group will not receive these results. Both groups will review their baseline and 12-week diabetes risk score results at the conclusion of the program and will be followed for an additional twelve weeks. Attendance rates and changes in weight, BMI, abdominal circumference, blood pressure, HgA1c, fasting blood glucose, cholesterol, and diabetes risk score will be compared between the groups.

Enrollment

223 patients

Sex

All

Ages

30 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women of all ethnic groups
  • ≥30 -75 years of age
  • Pre-diabetic defined as follows: fasting plasma glucose (FPG) 100-125mg/dL, HbA1c 5.7% to 6.4%.
  • Body Mass Index ≥ 25 kg/m2
  • Tricare beneficiary

Exclusion criteria

Diagnosis of type 1 or type 2 diabetes mellitus (defined as FPG ≥126 mg/dl on two different occasions or random blood sugar ≥200) If fasting glucose >= 126 only once, a second lab does not need to be arranged in an attempt to diagnose diabetes. It is acceptable for the patient to proceed in the trial. Also, Tethys lab results (e.g., fasting glucose and A1C) should not be used to make decisions about including or excluding patients in the trial. Only Air Force lab results should be used to make this determination.

  • Active duty military members
  • Patients with untreated hypothyroidism or previously diagnosed Cushing's syndrome
  • Subjects previously treated with metformin or thiazolidinediones in the previous 12 months
  • Psychological or physical disabilities deemed likely to interfere with participation in the study
  • Patients currently using weight-loss medications or medications known to affect body weight (i.e. chronic corticosteroid use)
  • Major medical conditions that prevent participation in the Group Lifestyle Balance Prevention Program (i.e. severe cardiovascular or cerebrovascular disease, severe renal or liver dysfunction, etc.)
  • Concurrent participation in a different weight loss program
  • Previous bariatric surgery
  • Unwilling to agree with the study assignments or provide informed consent
  • Participation in any other research project that would interfere with this protocol
  • Unable to read and write English
  • Pregnant or nursing patients
  • Female patients unwilling to undergo a pregnancy test or report possible pregnancy promptly and unwilling to take precautions to avoid pregnancy if potentially fertile during the study course

Discontinuation Criteria:

  • Consent is withdrawn
  • Death occurs
  • A woman becomes pregnant
  • Severe impairment of manual dexterity, vision, or intellectual function
  • They become lost to follow-up because of a move or transfer outside of the geographic area

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

223 participants in 2 patient groups

Control - diabetes risk score
Active Comparator group
Description:
the participants in the control group did not receive their diabetes risk score at the beginning of the trial, but did receive their scores to include baseline at the 12 and 24 week points.
Treatment:
Other: diabetic risk score
Intervention - diabetes risk score
Experimental group
Description:
the subjects in the intervention arm received their diabetes risk scores at the beginning of the trial, 12 weeks and 24 weeks.
Treatment:
Other: diabetic risk score

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems